Suven Life Sciences ahead of schedule in depression drug trial enrollment

Suven Life Sciences announced on December 11, 2025, that it has reached 100% patient enrollment for its Phase-2b clinical trial of Ropanicant (SUVN-911), a nicotinic α4β2 receptor antagonist for Major Depressive Disorder (MDD). This milestone was achieved more than two months ahead of the anticipated schedule, with 195 patients randomized across 35 sites in the USA.

The study, which initiated less than six months ago, will involve a six-week treatment duration to evaluate Ropanicant's efficacy and safety compared to placebo in improving depressive symptoms, as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Last patient out (LPO) is expected by the end of February 2026, with topline data readout anticipated in May 2026. Safety data from the study has been continuously monitored with no significant concerns reported to date.

Ropanicant is described as a novel, selective antagonist with intellectual property rights fully owned by Suven. The company highlighted strong engagement from investigators and participating patients, contributing to the rapid recruitment pace. This advancement marks a significant step in Suven's clinical development pipeline for CNS disorders.